Canaccord analyst Edward Nash raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the shares. The firm continues to believe Travere’s Filspari will be a dominant IgAN therapeutic amongst new approvals and late stage drugs for the treatment of IgAN.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target lowered to $27 from $31 at BofA
- Travere Therapeutics price target raised to $31 from $29 at BofA
- Promising Outlook for Travere Therapeutics: Buy Rating Affirmed Amid Regulatory and Market Opportunities
- Buy Rating for Travere Therapeutics Driven by sNDA Submission and Market Potential in FSGS
- Buy Rating for Travere Therapeutics Driven by Strategic Drug Developments and Regulatory Advancements